Sabrina Serani

The DermaSensor device is a noninvasive tool that can diagnose skin cancer, including the 3 most common types, right at the point of testing.

Findings from a phase 2 study found that treatment with axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma led to a complete metabolic response of 71%.

Positive findings from the KEYNOTE-A18 trial support the approval of pembrolizumab, radiotherapy, and concurrent chemotherapy in patients with high-risk locally advanced cervical cancer.

Health-related, mental, and emotional quality of life often suffer when patients with thyroid cancer undergo thyroidectomy. However, research shows it may be only in the short-term.

RC88 is a mesothelin-targeting antibody-drug conjugate that offers a novel approach to treating platinum-resistant ovarian, fallopian tube, and peritoneal cancers.

High complete response rates and low incidences of cytokine release syndrome and neurological events were observed when patients with relapsed or refractory mantle cell lymphoma were treated with lisocabtagene maraleucel.

The novel CDK9 inhibitor previously received orphan drug designations in relapsed/refractory acute myeloid leukemia and peripheral T-cell lymphoma.

The FDA completed an advice meeting with the manufacturer of olaptesed pegol in anticipation of the filing of an investigational new drug application in Q1 of 2024.

Combining a CDK9 inhibitor with venetoclax and prednisone led to encouraging responses in patients with lymphoid malignancies in the dose-escalation arm of a phase 1 clinical trial.

The FDA has approved the new drug application of a ready-to-dilute formulation of a treatment for breast and ovary adenocarcinoma.

The supplemental biologics license application approval is based on findings from the phase 3 innovaTV 301 trial investigating tisotumab vedotin vs investigator’s choice of chemotherapy in cervical cancer.

Findings from the phase 3 ASC4FIRST trial showed that asciminib demonstrated encouraging major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Findings from a phase 3 trial of the Bria-IMT regimen showed a 71% intracranial objective response rate in patients with breast cancer and central nervous system metastases.

Following a patient death in the phase 2 IOV-LUN-202 trial, the FDA has issued a clinical hold.

The investigational new drug application of lacutamab, a novel drug for advanced T-cell lymphoma, was put on partial clinical hold after the death of a patient last year.

A study evaluating healthcare expenses identified lisocabtagene maraleucel as a cost-effective second-line treatment for patients with diffuse large B-cell lymphoma.

The FDA did not fully approve sotorasib for the treatment of patients with KRAS G12C-mutated non–small cell lung cancer.

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

In an interview with Targeted Oncology, Daniel Wolff, MD, discussed findings from the phase 2 AGAVE-201 trial evaluating axatilimab as a potential treatment option for patients with chronic graft-vs-host disease.

The median overall survival at 19 months of patients with glioblastoma continues to benefit from treatment with olaptesed pegol plus radiation and bevacizumab.

Though climate change threatens everyone’s health and safety, those with cancer are increasingly vulnerable.

The phase 3 RELATIVITY-123 trial in metastatic microsatellite stable colorectal cancer is not expected to meet its primary end point upon completion and is being discontinued due to futility.

Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.

Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.

Findings from the phase 3 PERSEUS study found the safety profile of D-VRd in newly diagnosed multiple myeloma to be in line with the known profiles of the agents.

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naive HER2-positive breast cancer.

Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.

The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.

The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.

The phase 3 KEYLYNK-008 trial investigating pembrolizumab and olaparib in metastatic squamous non–small cell lung cancer will be stopped due to futility.